Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant careful consideration despite strong investor interest.
Market Samachar is a news aggregator. This article was originally published by Markets-Economic Times. Tap the button above to read the full story on their site.